Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented ( REGENSBURG Germany May 10th 2007

Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma today announced, that the abstract entitled “Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009” has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week. “The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule”, explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session “Gastrointestinal (Noncolorectal) Cancer”. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.

Page: 1 2
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Post Your Comments:

(Date:11/9/2009)...Ind. and MCDONOUGH, Ga., Nov. 9 /PRNewswire-FirstC...up today announced the formation of a joint ventur...a comprehensive range of surface replacement syste...d frame and as replacements for surfaces that are ...eful life. Hill-Rom, a global leader in patient s...

(Date:11/9/2009)...l., Nov. 9 Landauer, In... and environmental radiation monitoring services, ... in accordance with its long-term strategic priori...itions of Global Physics Solutions, Inc. (GPS) and..., President and CEO of Landauer. "These acquisitio...

(Date:11/9/2009)...PRINCETON, N.J., Nov. 9 ...ment will present at the Sixth Annual Lazard Capit...ill be held at the St Regis Hotel in New York City...rmasset,s President and Chief Executive Officer, w...y, November 18, 2009 at 3:45 PM (ET). ,, To acc...

Breaking Medicine Technology:Hill-Rom and Encompass Group Form Joint Venture 2 Hill-Rom and Encompass Group Form Joint Venture 3 Hill-Rom and Encompass Group Form Joint Venture 4 Hill-Rom and Encompass Group Form Joint Venture 5 Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 2 Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 3 Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 4 Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market 5 Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2 Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3 NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 1 NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 2 NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 3 NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 4 NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 5 CBI Announces Multi Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum 55824 1 CBI Announces Multi Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum 55824 2 Workers Compensation Networks Evolve to Meet Changing Needs of Todays Market 55820 1 Workers Compensation Networks Evolve to Meet Changing Needs of Todays Market 55820 2 Workers Compensation Networks Evolve to Meet Changing Needs of Todays Market 55820 3

[0] Hill-Rom and Encompass Group Form Joint Venture [0] Landauer Acquires Global Physics Solutions, Inc. as Platform to Expand Into Medical Physics Services Market [0] Pharmasset to Present at Lazard Capital Markets Healthcare Conference

...esident of SPRI,Clinical Trials, will be a feature...nplugged: The Trout Group Investor Seminar -- Mana... be held on Wednesday, July 30, at Midtown,Loft & ...s targeted to CEOs,and CFOs at private and small a...nsight into Wall Street and maximize communication...

...ences, GAITHERSBURG, Md., July 21 VIRxSYS Corpor...erapies for HIV and genetic,diseases, will present...ical trials for the media and members of the advoc...herapy for the treatment of AIDS. The,presentation...a.m. EDT. The,presentation can be accessed through...

Other Medicine Technology:VIRxSYS to Host a Web Conference to Announce Clinical Trial Update 2 VIRxSYS to Host a Web Conference to Announce Clinical Trial Update 3 VIRxSYS to Host a Web Conference to Announce Clinical Trial Update 4 VIRxSYS to Host a Web Conference to Announce Clinical Trial Update 5

Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30 VIRxSYS to Host a Web Conference to Announce Clinical Trial Update

(Date:11/9/2009)...-Asia-FirstCall/ -- Mindray Medical,International ...turer and,marketer of medical devices worldwide, a...sults for the third quarter and nine months ended ...ons as of September 30, 2009, -- Third quarter ... of, 3.1% over the third quarter of 2008. Fi...

(Date:11/9/2009)...romise to not expand abortion ,, Senate must ...ed for poor, elderly ,, WASHINGTON, Nov. 9 /PR... Chicago, president of the United States Conferenc...ion of the U.S. House of Representatives to block ...lective abortions. ,, In a statement issued No...

(Date:11/9/2009)...riance Across the World is Critical in Understandi... (Vocus) November 9, 2009 -- Understanding patient...e when analyzing and interpreting scientific resul...d the genomes of 4,000 people throughout Europe an... and Michael F. Seldin of the University of Califo...

(Date:11/9/2009)...ual function, study says, , , MONDAY,...to restore sexual function to rabbits with damaged...nd implanting it, a new study reports. , Though...y the technique could one day be used to treat sev...e to show the tissue was able to integrate and fun...

(Date:11/9/2009)...ed in April 2010, Provides First Responders with a...idge, MA (Vocus) November 9, 2009 -- When Stefan S...inspected a suspected mass grave at Dasht-e-Leili... of experts to help interpret the scene. He knew t...step in securing evidence of a human rights violat...

[0] Mindray Announces Third Quarter 2009 Financial Results [0] Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly [0] News from the November/December Issue of Molecular Medicine [0] Scientists Grow New Penile Tissue in the Lab [2] Physicians for Human Rights Offers Training in Crime Scene Documentation

...celebrated the world over as the World Population ...ons Population Fund in 1988, to mark the occasion .... // The aim of the day is to draw attention...opmental plans and the ensuing overall progress. ...

...fered cardiac death would have their bodies prepar.... The Australian Health Ethics Committee that ...the transplant preparations to patients who are ce...after the cessation of blood circulation. In the p...

...tests at this year's World Cup till now, football'...'s chief medical officer Jiri Dvorak confirmed tha...s had returned negative while the number of injuri...d to date, giving an average of 2.2 injuries per m...

...ifornia, San Diego have found that the main color ...on the mainland//, but lighter on the barrier isla...ely due to a simple genetic mutation. Their d...st subunit of a gene—can affect the survival and e...

...ealth and Human Services, on behalf of the Indian ...derstanding pledging to collaborate in seeking way...ses in American Indian and Alaska Native communiti...t 1:30 p.m. at the Annenberg Plaza, Mayo Clinic in...

...sts of the Rostock Center for the study of Demogra...f working hours will be //soon reduced, if the tre...r market continue. The Rostock Center is a re...at the institute explained that demographic change...

Other Medicine News:Health News:'Young and their Reproductive Health' - Theme of World Population Day 2 Health News:Genetic Mutation in Mice Suggests Extinct Mammoth Had Light and Dark Fur 2 Health News:Genetic Mutation in Mice Suggests Extinct Mammoth Had Light and Dark Fur 3 Health News:Mayo Clinic and Indian Health Service Form Clinical Practice Collaboration 2 Health News:Demographic Change Demand a New Life-Course for Aging Society 2

'Young and their Reproductive Health' - Theme of World Population Day Organ Donation from Cardiac Death Patients World Cup: No Positive Doping Tests, Fewer Injuries Genetic Mutation in Mice Suggests Extinct Mammoth Had Light and Dark Fur Mayo Clinic and Indian Health Service Form Clinical Practice Collaboration Demographic Change Demand a New Life-Course for Aging Society

...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...

Medicine Products:

Creatine Kinase, Total, Serum or Plasma C-Reactive Protein, Neonatal C-Peptide, 24-Hour Urine Coxsackie A9 Virus Antibodies by CF

( REGENSBURG Germany May 10th 2007 - ...)Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented,Health